You are here
Geom Therapeutics To Present Data From Antibiotic Drug Development Programs At ECCMID
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Geom Therapeutics, Inc., a privately held biopharmaceutical company focused on the development of novel antibiotics for multidrug-resistant (MDR) gram-negative infections, today announced upcoming data presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands from April 13 to 16, 2019. One poster and one oral presentation demonstrating the mechanism of action and efficacy driver of GT-055, a novel dual-action beta-lactamase inhibitor, in combination with GT-1, a siderophore cephalosporin with a novel uptake mechanism, have been accepted for presentation.
Dirk Thye, M.D., Executive Chairman of Geom Therapeutics, Inc., said, "GT-1 and GT-055 are intended for the treatment of multidrug-resistant gram-negative infections, including infections caused by species of Enterobacteriaceae, Acinetobacter and Pseudomonas. Infections caused by these multidrug resistant organisms are among the most critical threats to human health and wellness. Geom's GT-1 and GT-1/GT-055 programs continue to advance through development, and the data presented at ECCMID highlight the advantages of combining GT-1 with GT-055, a new beta-lactamase inhibitor. The poster presentation demonstrates the dual-action mechanism of GT-055 and the oral presentation describes the PK/PD relationship of the drug combination, which results in highly achievable efficacy targets and a low frequency of resistance."
Details of the ECCMID 2019 presentations are as follows:
Sunday, April 14th
Oral Session: New beta-lactamase inhibitors: in vitro studies agents (1:30 p.m. – 2:30 p.m.)
- P1186: Penicillin-binding protein activity of beta-lactamase inhibitor GT-055. J. Lee
Tuesday, April 16th
Poster Session: Defining exposure, efficacy and safety of new antimicrobial agents (11:00 a.m. – 12:00 p.m.)
- O1060: Pharmacokinetics-pharmacodynamics of the novel beta-lactamase inhibitor GT-055 in combination with the siderophore cephalosporin GT-1; B. VanScoy
Copies of all poster presentations will be available on the Geom website following the ECCMID meeting: http://www.Geomtherapeutics.com/
GT-1, a novel siderophore cephalosporin antibiotic, is in development for the treatment of MDR gram-negative bacterial infections. GT-1's siderophore moiety binds to extracellular free iron and – unlike all approved beta-lactam antibiotics – is actively transported across the outer membrane by bacterial siderophore receptors. This leads to increased concentrations in the bacterial periplasmic space where GT-1 binds to its penicillin-binding protein targets and disrupts cell wall synthesis, leading to cell death. The active transport into bacterial cells potentiates activity against gram-negative bacteria, including MDR Acinetobacter spp. and P. aeruginosa. GT-1 has potent in vitro activity and in vivo efficacy against MDR gram-negative pathogens. All IND-enabling studies have been completed for GT-1. For more information about GT-1, please visit http://www.geomtherapeutics.com/gt-1.
GT-055, a novel dual-action β-lactamase inhibitor (BLI), was discovered through a focused medicinal chemistry effort designed to identify the optimal BLI partner for GT-1 based on BLI coverage, PK, efficacy and safety. GT-055 inhibits members of all four classes of β-lactamases, including ESBLs and carbapenemases, and also exhibits intrinsic antibacterial activity via PBP2 binding against certain Enterobacteriaceae.
About Geom Therapeutics
Geom Therapeutics is a biopharmaceutical company focused on the development of novel antibiotics for MDR gram-negative infections. Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1. GT-1, our lead product candidate, a novel siderophore cephalosporin, has demonstrated broad spectrum efficacy against gram-negative pathogens and is in development for the treatment of serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. Geom is also developing GT-055, a novel dual-action beta-lactamase inhibitor, in combination with GT-1. GT-1/GT-055 is currently in preclinical studies and intended for treatment of MDR gram-negative infections. We have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Our mission is to improve patients' lives by developing novel antibiotics to treat resistant infections for which there are no available therapies. For more information, please visit www.geomtherapeutics.com.
SOURCE Geom Therapeutics, Inc.